People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its members, a blow to rival Eli Lilly & Co.’s Zepbound that was moved off the ...

As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from ... "In our view, the Novo/CVS deal does not represent the beginning of an obesity pricing war between ...

CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a more affordable price. Starting July 1, 2025, Wegovy will become the ...

The trial included 751 people from across the U.S. who were overweight or had obesity ... CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered ...

Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand for its diabetes and obesity ... products. CVS said the change aims to offer ...

Word spread quickly online about the change after Caremark ... employer clients paid for obesity drugs by 10% to 15% compared with the previous year. Advertising “CVS Caremark was able to ...